Friday, March 24, 2023
Ono Pharmaceutical announced that it has entered into a drug discovery collaboration agreement with MOLCURE to discover and develop innovative antibody drugs for multiple targets utilizing MOLCURE’s AI-driven platform technology.
The new collaboration will accelerate biologics drug discovery efforts and bring innovative drugs for patients as soon as possible and will improve the prognosis and quality of life for patients around the world.
Under the terms of the agreement, MOCLURE will discover and identify antibodies or molecules for multiple targets of interest selected by Ono, using MOLCURE’s proprietary AI-driven platform technology. Ono will obtain option rights to exclusively and globally develop and commercialise therapeutic antibody drug candidates generated through the collaboration. Ono will pay to MOLCURE an upfront payment and research funding, and success-based milestone payments on research, development and commercialisation, as well as tiered royalties based on global net sales.
